Thomas Hogan Sells 139,713 Shares of Cellebrite DI (NASDAQ:CLBT) Stock

Cellebrite DI Ltd. (NASDAQ:CLBT) CEO Thomas Hogan sold 139,713 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $15.39, for a total transaction of $2,150,183.07. Following the completion of the sale, the chief executive officer owned 790,548 shares of the company’s stock, valued at approximately $12,166,533.72. The trade was a 15.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Cellebrite DI Stock Performance

Shares of CLBT stock opened at $11.14 on Friday. The firm has a market capitalization of $2.78 billion, a price-to-earnings ratio of 50.64, a price-to-earnings-growth ratio of 1.34 and a beta of 1.18. Cellebrite DI Ltd. has a one year low of $9.58 and a one year high of $19.98. The company has a 50 day moving average price of $14.47 and a 200 day moving average price of $14.03.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings results on Thursday, August 13th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.05. Cellebrite DI had a net margin of 11.43% and a return on equity of 16.04%. The company had revenue of $131.14 million for the quarter, compared to analyst estimates of $131.50 million. As a group, equities analysts forecast that Cellebrite DI Ltd. will post 0.41 EPS for the current fiscal year.

Hedge Funds Weigh In On Cellebrite DI

Several hedge funds and other institutional investors have recently made changes to their positions in CLBT. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Cellebrite DI by 16.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 173,013 shares of the company’s stock worth $3,362,000 after purchasing an additional 24,881 shares during the period. Geode Capital Management LLC increased its holdings in Cellebrite DI by 16.2% in the 2nd quarter. Geode Capital Management LLC now owns 314,440 shares of the company’s stock valued at $5,029,000 after purchasing an additional 43,898 shares in the last quarter. Invesco Ltd. raised its position in Cellebrite DI by 6.4% in the second quarter. Invesco Ltd. now owns 3,505,552 shares of the company’s stock valued at $56,089,000 after purchasing an additional 209,473 shares during the period. First Trust Advisors LP purchased a new position in Cellebrite DI in the second quarter valued at about $341,000. Finally, Marshall Wace LLP acquired a new position in shares of Cellebrite DI during the second quarter worth about $4,472,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI News Roundup

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Second-quarter adjusted EPS was $0.11, above the $0.05 consensus estimate cited by MarketBeat. Management also raised its adjusted EBITDA target, while subscription revenue continued to grow. Cellebrite second-quarter earnings report
• Positive Sentiment: Lake Street, JPMorgan, D.A. Davidson and Needham lowered their price targets but retained positive ratings: Buy or Overweight. Their revised targets range from $12.50 to $16, implying roughly 12% to 44% upside based on the provided reference price. Analyst price-target updates
• Positive Sentiment: Unusual options activity included nearly 20,000 call contracts, far above average volume, indicating speculative positioning for a potential rebound.
• Neutral Sentiment: Cellebrite completed a planned CEO transition, with Shiven Ramji succeeding Thomas E. Hogan effective August 13. The change may support a strategic reset, but investors face uncertainty during the leadership handoff. CEO succession announcement
• Negative Sentiment: The key catalyst for the selloff was lowered guidance. Third-quarter revenue is expected at $145 million-$148 million, below the $150.3 million consensus, while full-year revenue guidance of $555 million-$561 million trails the $568.1 million estimate. The company also reduced its 2026 ARR outlook. Cellebrite outlook announcement
• Negative Sentiment: Quarterly revenue of $131.14 million was slightly below the $131.87 million estimate. The earnings beat was therefore overshadowed by weaker growth indicators and the reset to management’s outlook.
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations and whether prior projections and disclosures were accurate. The investigations are allegations, not findings, but add legal and reputational risk. Cellebrite investigation notice
• Negative Sentiment: Former CEO Thomas Hogan sold 139,713 shares worth approximately $2.15 million, reducing his holdings by about 15%. Although the sale may reflect the transition or personal financial planning, its timing weighs on investor sentiment. SEC insider trading filing

Wall Street Analyst Weigh In

CLBT has been the subject of a number of research reports. Lake Street Capital lowered their price target on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a research report on Friday. Weiss Ratings downgraded Cellebrite DI from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday. JPMorgan Chase & Co. reduced their price objective on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating on the stock in a research note on Friday. DA Davidson reduced their price objective on Cellebrite DI from $22.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Needham & Company LLC decreased their target price on Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a report on Friday. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $16.70.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.